The Effect of Tofogliflozin Treatment on Postprandial Glucose and Lipid Metabolism in Japanese Men With Type 2 Diabetes: A Pilot Study. - Wikidata - wikimedia - TriplyDB

The Effect of Tofogliflozin Treatment on Postprandial Glucose and Lipid Metabolism in Japanese Men With Type 2 Diabetes: A Pilot Study.

The Effect of Tofogliflozin Treatment on Postprandial Glucose and Lipid Metabolism in Japanese Men With Type 2 Diabetes: A Pilot Study.

http://www.wikidata.org/entity/Q37737187

about

Effects of Six Kinds of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Parameters, and Summarized Effect and Its Correlations With Baseline Data Sodium-Glucose Cotransporter 2 Inhibitors Reduce Prandial Insulin Doses in Type 2 Diabetic Patients Treated With the Intensive Insulin Therapy.

P2860

Q33763316-22DC5405-4D13-4D0A-83DB-BC4A6092BE31 Q55513324-E2F7AA36-E132-4FDD-8E2E-01030347F5E9

P2860

The Effect of Tofogliflozin Treatment on Postprandial Glucose and Lipid Metabolism in Japanese Men With Type 2 Diabetes: A Pilot Study.

http://www.wikidata.org/entity/Q37737187

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on April 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

The Effect of Tofogliflozin Tr ...... ype 2 Diabetes: A Pilot Study.

@en

The Effect of Tofogliflozin Tr ...... ype 2 Diabetes: A Pilot Study.

@nl

type

label

The Effect of Tofogliflozin Tr ...... ype 2 Diabetes: A Pilot Study.

@en

The Effect of Tofogliflozin Tr ...... ype 2 Diabetes: A Pilot Study.

@nl

prefLabel

The Effect of Tofogliflozin Tr ...... ype 2 Diabetes: A Pilot Study.

@en

The Effect of Tofogliflozin Tr ...... ype 2 Diabetes: A Pilot Study.

@nl

P1433

Q37737187-BC876031-6E90-4CA5-83CD-B1C72B9FB6D4

P1476

Q37737187-E19F6D61-F539-4E29-B6BB-11F9725673AC

P2093

Q37737187-6A4C47BB-4279-4DA4-9E68-5DFB8CD1FF25

Q37737187-9F8777F7-1BF8-4D10-992F-ABC1858FB4C9

Q37737187-A99C2237-7FB3-4238-B3F0-113127C39FBF

Q37737187-B0DD82C4-9CBA-4971-951C-032B23617613

Q37737187-CFD5EF43-21E3-4BDE-9661-F8553D22E57D

P2860

Q37737187-087C7AD8-4A1F-4A6E-9178-66020D983816

Q37737187-135180F2-A7D4-43A3-8AA9-0687AF59E835

Q37737187-14CA739B-1FAC-455F-81C9-252972DF10E3

Q37737187-1DC0B2B0-EDF1-47FB-83B1-766DFC502E81

Q37737187-31A36A6C-674D-4E41-B391-5B8F7872A18D

Q37737187-3E6562A6-04E8-4DB3-B356-346DEFBCD9BA

Q37737187-4A2828D0-BE99-4FEE-9EBA-24AC8A05A16C

Q37737187-4AF33C62-5F27-4A64-9CB8-17349CBC6BE7

Q37737187-4C8241E1-4DD7-48E5-967F-FF85A819707C

Q37737187-525C9ECA-70E3-4AD4-98A6-B6A3275DE427

P304

Q37737187-58213B9A-C609-4C6B-983A-157A1382CD5B

P31

Q37737187-17AA3D8E-6CEF-484A-8D05-DE6EC31555A2

P356

Q37737187-1131C07F-2852-4C3F-893F-00715FC26A8A

P433

Q37737187-64FD23E4-F426-4DBC-AE65-6EFDB82D2D00

P478

Q37737187-43FD25D1-DB76-4508-BE3A-1BC358547E2F

P577

Q37737187-43C1F4E1-B0F2-443E-9776-7BC3C20A1109

P698

Q37737187-72FBA455-D56C-46A9-B6B1-128BE76DD721

P921

Q37737187-DF2E2D5E-83E7-4F64-A159-37515A0DCA62

Q37737187-f770165c-0b51-46ce-8475-1ef526fc7b4d

P932

Q37737187-3D262B3B-C3C9-4BD9-8D66-C87D5341C80C

P356

P1433

Journal of clinical medicine research

P1476

The Effect of Tofogliflozin Tr ...... ype 2 Diabetes: A Pilot Study.

@en

P2093

Hirokazu Kakuda

http://www.w3.org/2001/XMLSchema#string

Junji Kobayashi

http://www.w3.org/2001/XMLSchema#string

Masahiro Kakuda

http://www.w3.org/2001/XMLSchema#string

Masaru Sakurai

http://www.w3.org/2001/XMLSchema#string

Noboru Takekoshi

http://www.w3.org/2001/XMLSchema#string

P2860

Hormone-sensitive lipase: sequence, expression, and chromosomal localization to 19 cent-q13.3

Very short-term effects of the dipeptidyl peptidase-4 inhibitor sitagliptin on the secretion of insulin, glucagon, and incretin hormones in Japanese patients with type 2 diabetes mellitus: analysis of meal tolerance test data.

Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria.

Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group compar

Postprandial lipoprotein metabolism and atherosclerosis.

Remnant lipoproteins as therapeutic targets.

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.

Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus.

Hormonal regulation of hormone-sensitive lipase in intact adipocytes: identification of phosphorylated sites and effects on the phosphorylation by lipolytic hormones and insulin.

P304

403-409

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.14740/JOCMR2806W

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28392860

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

5380173

http://www.w3.org/2001/XMLSchema#string